Overview

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well monoclonal antibody therapy, chemotherapy, and peripheral stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Nebraska

Treatments:

Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Carmustine
Cytarabine
Etoposide
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Melphalan
Tositumomab I-131